N.v. Organon

Merck Sharp + Dohme B.v.

Merck Sharp + Dohme Corp.

Msd Oss B.v.

Willem Frederik Johan Karstens

Cornelis Marius Timmers

Kenneth Jay Barr

Hongjun Zhang

Richard Thomas Beresis

Hubert Jan Jozef Loozen

Dongshan Zhang

Rita Corte Real Goncalves Azevedo

Xiaobang Duan

Mario Van Der Stelt

Jos Cals

Ralf Plate

Paolo Giovanni Martino Conti

Pedro Manuel Grima Poveda

Christianus Johannes Van Koppen

Rachel Deborah Van Rijn

Hubert Jan Josef Loozen

Lars Anders Van Der Veen

The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition. 

RORgammaT inhibitors

The present invention relates to compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

The present invention relates the use of a compound, a pharmaceutical composition, compounds and a kit for treating or preventing disorders in a mammal responsive to TSH receptor mediated pathways, including disorders such as hyperthyroidism, Graves' disease, Graves Ophthalmopathy, Graves' associated pretibial dermopathy, nodular goitre and thyroid cancer comprising administering to said mammal an effective amount of a tetrahydroquinoline compound of Formula (I) or an pharmaceutically acceptable salt thereof. 

TSH receptor antagonizing tetrahydroquinoline compounds

The invention relates to 5,6-dihydropyrrolo[2,1-&#x3b1;]isoquinoline and pyrrolo[2,1-&#x3b1;]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility. 

(Dihydro)pyrrolo[2,1-&#x3b1;]isoquinolines

The present invention relates to 4-phenyl-5-oxo-1,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein Ris (1-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R, Rare independently halogen, (1-4C)allcyl, (2-4C)alkenyl, (2-4C)-alkynyl, (1-4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; Ris phenyl or (2-5C)-heteroaryl, both substituted with Rand optionally substituted on the (hetero)aromatic ring with one or more substituents selected from hydroxy, amino, halogen, nitro, trifluoromethyl, cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylthio and (di)(1-4C)-alkylamino. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline derivatives in therapy, more specifically for the treatment of infertility.

4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives for the treatment of infertility

The present invention relates to 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives having the general Formula (I) wherein the substituents are defined as in the description, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives in therapy, more specifically for the treatment of fertility disorders. 

4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility

A bicyclic heteroaromatic compound according to general formula I, or a pharmaceutically acceptable salt thereof, wherein

Bicyclic heteroaromatic compounds

A bicyclic heteroaromatic compound according to general formula I, or a pharmaceutically acceptable salt thereof, wherein The compounds of the invention can be used in fertility regulation therapies.

Growing community of inventors

Oss, Netherlands

Willem Frederik Johan Karstens